2024-03-29T13:32:56Z
https://niigata-u.repo.nii.ac.jp/oai
oai:niigata-u.repo.nii.ac.jp:00021634
2022-12-15T03:52:07Z
453:456
471:537:538:1189
New Drugs for DIC
5) DICの新しい治療薬F(シンポジウム DIC-診断・治療の最近の動向, 第457回新潟医学会)
5) DICの新しい治療薬F(シンポジウム DIC-診断・治療の最近の動向, 第457回新潟医学会)
帯刀, 亘
132008
low molecular weight heparin
synthetic protease inhibitor
activated protein C
低分子ヘパリン
合成蛋白分解酵素阻害剤
活性化プロテインC
Heparin has long been used for disseminated intravascular coagulation (DIC), but recently some new drugs have become available for DIC. The concentrate of Antithrombin III, which is a physiological protease inhibitor, is used in combination with heparin. Low molecular weight heparin (LMWH) with molecular weight of about 4000~6000 has more anti-X_a activity than anti-IIa activity. For this reason, LMWH has an anticoagulant activity with a low bleeding risk. Synthetic protease inhibitors (eg. FUTHAN) directly inhibit several protease activities in the absence of antithrombin III. Activated protein C inactivates V_a and VIII_a with protein S as a cofactor, and inhibits plasminogen activator inhibitor. Its concentrate may be effective for patients with DIC especially caused by endotoxicemia. DIC is heterogeneous in coagulation-fibrinolysis balance and is associated with various diseases, so we must choose suitable drugs for individual patients.
departmental bulletin paper
新潟医学会
1991-02
application/pdf
新潟医学会雑誌
2
105
103
108
新潟医学会雑誌
AN00182415
00290440
https://niigata-u.repo.nii.ac.jp/record/21634/files/105(2)_103-108.pdf
jpn